A study puts first-year GLP-1 discontinuation somewhere between a fifth and half of patients. The source shared the figure without naming the study.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A video walks through retatrutide and how targeting GIP and glucagon alongside GLP-1 sets it apart from current drugs.
Novo Nordisk plans to offer Wegovy in vials as well as its usual format. The report gives no timing or pricing yet.
Loading…